BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
46 hedge funds and large institutions have $1.04M invested in BRAINSTORM CELL THERAPUTC in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 16 closing their positions.
12% more capital invested
Capital invested by funds: $928K → $1.04M (+$111K)
2.56% less ownership
Funds ownership: 10.65% → 8.08% (-2.6%)
13% less funds holding
Funds holding: 53 → 46 (-7)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
52% less call options, than puts
Call options by funds: $23K | Put options by funds: $48K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCG
Weaver Consulting Group
Huntington Beach,
California
|
+$20K |
| 2 |
VF
Virtu Financial
New York
|
+$14.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.25K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.96K |
| 5 |
Barclays
London,
United Kingdom
|
+$4.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$41K |
| 2 |
GS
GTS Securities
Miami,
Florida
|
-$40.5K |
| 3 |
Millennium Management
New York
|
-$35.1K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$27.3K |
| 5 |
Two Sigma Investments
New York
|
-$15.4K |
BCLI Hedge Fund Activity: Q4 2023 in Review
46 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2023, worth a combined $1.04M — up 12% from $928K a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of BCLI and 9 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Weaver Consulting Group, adding an estimated $20K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $41K sold.
- 46 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2023, down from 53 in Q3 2023.
- Funds reported $1.04M of BRAINSTORM CELL THERAPUTC stock for Q4 2023, up 12% quarter-over-quarter.
- 9 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2023 and 16 closed out, a net change of -7 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2023 was Weaver Consulting Group, an estimated $20K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2023 was Renaissance Technologies, an estimated $41K sold.
Based on aggregated 13F filings for Q4 2023.